Precipio (NASDAQ:PRPO) Stock Price Crosses Below 200 Day Moving Average of $8.35

Precipio, Inc. (NASDAQ:PRPOGet Free Report) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $8.35 and traded as low as $8.28. Precipio shares last traded at $8.53, with a volume of 4,732 shares changing hands.

Precipio Trading Up 0.7 %

The business has a 50 day moving average of $6.72 and a two-hundred day moving average of $8.35. The company has a current ratio of 0.92, a quick ratio of 0.81 and a debt-to-equity ratio of 0.01. The firm has a market cap of $11.75 million, a P/E ratio of -0.93 and a beta of 1.89.

Precipio (NASDAQ:PRPOGet Free Report) last issued its quarterly earnings data on Friday, August 11th. The biotechnology company reported ($1.80) earnings per share for the quarter. The company had revenue of $3.53 million during the quarter. Precipio had a negative net margin of 98.50% and a negative return on equity of 68.59%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Precipio stock. Virtu Financial LLC bought a new position in shares of Precipio, Inc. (NASDAQ:PRPOFree Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 45,146 shares of the biotechnology company’s stock, valued at approximately $25,000. Virtu Financial LLC owned 0.20% of Precipio at the end of the most recent quarter. Institutional investors and hedge funds own 16.43% of the company’s stock.

Precipio Company Profile

(Get Free Report)

Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests.

Further Reading

Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with's FREE daily email newsletter.